Key regions: Germany, United States, India, Japan, United Kingdom
The Anti-Rheumatic Drugs market in Guinea has seen a steady growth in recent years.
Customer preferences: Patients in Guinea suffering from rheumatoid arthritis have shown a preference for biologic drugs due to their effectiveness in treating the disease. Biologics such as TNF inhibitors and interleukin inhibitors have proven to be more effective in reducing inflammation and slowing down the progression of the disease. However, due to their high cost, many patients are unable to afford them.
Trends in the market: The market for Anti-Rheumatic Drugs in Guinea has been growing due to an increase in the prevalence of rheumatoid arthritis in the country. The disease affects a significant proportion of the population, and the demand for effective treatments has been on the rise. The market has also seen a shift towards biologic drugs, which are more effective in treating the disease. However, the high cost of these drugs has limited their availability to a small section of the population.
Local special circumstances: Guinea is a low-income country, and the cost of healthcare is a significant barrier for many patients. The government has limited resources to invest in healthcare, and the burden of healthcare falls largely on the patients themselves. Many patients are unable to afford the high cost of biologic drugs, and this has limited their access to effective treatments.
Underlying macroeconomic factors: The economy of Guinea has been growing steadily in recent years, but it remains one of the poorest countries in the world. The country has a high burden of disease, and the healthcare system is underfunded and poorly equipped. The government has limited resources to invest in healthcare, and this has resulted in a lack of access to essential medicines for many patients. The high cost of biologic drugs has also limited their availability in the country. Despite these challenges, the market for Anti-Rheumatic Drugs in Guinea is expected to continue to grow in the coming years, driven by an increase in the prevalence of rheumatoid arthritis and a growing demand for effective treatments.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
